Celecoxib对肺癌细胞的辐射增敏实验研究

目的 建立裸鼠非小细胞肺癌(NSCLC)H460细胞动物模型,观察环氧化酶2(COX-2)选择性抑制剂塞来昔布(Celecoxib)对H460放疗的增敏作用,并对其作用机理进行初步探讨。方法 建立Balb/c裸鼠肿瘤模型。动物随机分成3组:对照组、放疗组、塞来昔布+放疗组。灌肠法给予塞来昔布16mg/kg/d,4周时对比两组肿瘤瘤重;免疫组化方法分析共济失调-毛细血管扩张症突变蛋白(ATM)和表皮生长因子受体(EGFR)表达变化。结果 4周时塞来布昔+放疗组与放疗组的抑瘤效果比较有显著差异(P < 0.05)。结论 塞来昔布可能通过提高ATM和EGFR的表达,增强H460细胞的放疗敏感性,将来可能具有较好的临床应用价值。

Study on the Radiosensitization on Lung Cancer Induced by Celecoxib

Objective Nude mice model of nonsmall-cell lung cancer(NSCLC) H460 cell was established to investigate the combined effects of radiotherapy and celecoxib. Methods Athymic mice bearing H460 were randomly divided into 3 groups:control, radiotherapy and radiotherapy plus celecoxib group. 4 weeks after treatment,mice were killed to detect tumor weight. The expressions of ataxia-telangiectasia mutated(ATM) and epidermal growth factor receptor(EGFR) in tumor tissues were detected by immune-histochmical (S-P) method. Results The tumor weight of radiotherapy plus celecoxib group was significantly different with that of radiotherapy group (P < 0.05). The expressions of ATM and EGFR were significantly lower than that in radiotherapy group. Conclusion Celecoxib promotes radiotherapeutic sensitivity of H460 by down-regulating the expression of ATM and EGFR. Celecoxib may presents potency in curing human lung cancer.